SynCardia Goes Social on Facebook, Twitter and LinkedIn
World's Only Approved Total Artificial Heart Becoming Standard of Care for End-Stage Biventricular Heart Failure
TUCSON, Ariz. – Aug. 31, 2011 – SynCardia Systems, Inc., manufacturer of the SynCardia temporary Total Artificial Heart, announced today that it has launched company pages on Facebook, Twitter and LinkedIn in order to educate a larger audience about the world's only FDA, Health Canada and CE (Europe) approved Total Artificial Heart. There have been more than 950 implants of the Total Artificial Heart, accounting for more than 230 patient years of life on the device.
Recently, SynCardia Certified Centers and their Total Artificial Heart patients have made headlines worldwide. On Aug. 2, Papworth Hospital became the first hospital in the United Kingdom to discharge a SynCardia Total Artificial Heart patient to wait for a matching donor heart at home. Matthew Green was able to leave the hospital using the Freedom® portable driver, a wearable power supply for SynCardia's Total Artificial Heart.
A week later, on Aug. 9, University of Iowa Hospitals and Clinics discharged the first Total Artificial Heart patient in the Midwest to wait for a matching donor heart at home. Richard Whittington, 59, received SynCardia's Total Artificial Heart on July 6 and after 34 days was discharged from the hospital on Aug. 9. Mr. Whittington is participating in the FDA-approved Investigational Device Exemption (IDE) clinical study of the Freedom portable driver.
In June, Texas Children's Hospital announced it had become the world's first pediatric hospital to implant SynCardia's Total Artificial Heart to save the life of 17-year-old Jordan Merecka. Jordan, who was born with multiple congenital heart defects and is awaiting a transplant, had progressed to end-stage biventricular failure. Jordan is only the third congenital heart patient under the age of 18 in the U.S. and the 6th in the world to be implanted with SynCardia's Total Artificial Heart.
The Freedom portable driver is CE approved for use in Europe and undergoing an IDE clinical study in the U.S. To date, 57 patients have been supported by the Freedom driver worldwide. In the U.S., 28 patients have been enrolled in the FDA clinical study, with 17 of these patients being discharged home. This is more than half of the 30 discharge patients required by the FDA study. Weighing 13.5 pounds, the Freedom driver is the first U.S. portable driver designed to power the Total Artificial Heart both inside and outside the hospital.
CAUTION – The Freedom® portable driver is an investigational device, limited by United States law to investigational use.
About SynCardia Systems, LLC
SynCardia Systems, LLC in Tucson, Ariz., is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. For people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure), the SynCardia temporary Total Artificial Heart is used as a bridge to transplant, helping them survive until a matching donor heart becomes available. SynCardia also manufactures the Freedom® portable driver, which powers the SynCardia Total Artificial Heart and allows clinically stable patients to be discharged from the hospital to enjoy life at home while they wait for a heart transplant.
Janelle Drumwright, email@example.com, (520) 547-7463